Supplemental material
Future Oncology
Volume 20, 2024 - Issue 16: Future Oncology
Short Communication
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
William Wong1 Genentech, Inc., South San Francisco, CA 94080, USACorrespondence[email protected]
https://orcid.org/0000-0002-6054-278XView further author information
https://orcid.org/0000-0002-6054-278XView further author information, Stacey Kowal1 Genentech, Inc., South San Francisco, CA 94080, USAhttps://orcid.org/0000-0001-6018-6052View further author information
https://orcid.org/0000-0001-6018-6052View further author information, Tu My To1 Genentech, Inc., South San Francisco, CA 94080, USAhttps://orcid.org/0000-0001-9506-7539View further author information
https://orcid.org/0000-0001-9506-7539View further author information, , David Veenstra2 Department of Pharmacy, University of Washington, Seattle, WA 98195, USA;3 Curta, Inc., Seattle, WA 98116, USAhttps://orcid.org/0000-0003-0687-0480View further author information
https://orcid.org/0000-0003-0687-0480View further author information, Louis Garrison2 Department of Pharmacy, University of Washington, Seattle, WA 98195, USA;4 VeriTech Corporation, Mercer Island, WA 98040, USAhttps://orcid.org/0000-0002-9468-4989View further author information
https://orcid.org/0000-0002-9468-4989View further author information & Meng Li5 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAhttps://orcid.org/0000-0002-8537-7872View further author information
https://orcid.org/0000-0002-8537-7872View further author information show all